338 results about "Steroid hormone" patented technology

The present invention relates to methods and kits for reducing the occurrence of preterm delivery and other pregnancy-related conditions in pregnant female subjects exhibiting one or more risk factors for preterm delivery and other pregnancy-related conditions. For example, the present invention relates to methods for reducing the occurrence of preterm delivery in a pregnant female subject having no history of preterm delivery and exhibiting one or more risk factors for preterm delivery (e.g., smoking during pregnancy). The methods and kits provide for the administration of a steroid hormone to the pregnant female subject.

The decomposer film product has a polymeric decomposer layer, a cover layer for protecting the decomposer film from the surroundings and a releasable support liner, which is removed prior to use. The polymeric decomposer film contains a water-soluble or water-insoluble polymeric adhesive material and a decomposition accelerator, which acts to decompose an effective ingredient, such as a steroid hormone, of a worn or unused transderamal patch, when the effective ingredient releasing layer of the patch adheres to the polymer film, so that the pharmaceutical effective ingredient comes into contact with the decomposition accelerator by diffusion. The decomposition accelerator includes a chemically oxidizing substance, preferably urea peroxide, manganese (III) acetate or iron (III) citrate. The water-insoluble polymeric adhesive material is preferably an acrylates adhesive. The water-soluble polymeric adhesive material is preferably polyvinyl alcohol, polyvinyl pyrrolidone, a cellulose derivative or a polyacrylic acid.

The invention relates to methods and pharmaceutical compositions for inhibiting or preventing preterm birth, inhibiting or delaying cervical ripening, inhibiting myometrial contractility and treating or inhibiting uterine contractility disorders. The methods comprise administering an effective amount of a composition comprising steroid hormones such as soluble progesterone.

Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.

The present invention relates to steroid hormone products, such as oral contraceptive products, including at least one steroid active ingredient mixed with an excipient and having improved dissolution and release rate properties. The invention further relates to methods for making such steroid hormone products, wherein a mixture of the hormone and the excipient is subjected to sufficient mechanical energy to form a powder blend wherein the hormone is stabilized by the excipient in substantially non-crystalline form.

An agent for treating various kinds of diseases which contains at least one selected from the group consisting of sexual steroid hormone such as estrogen or its metabolites, its derivative, structural analogues thereof, estrogen acting substance or SERM non-feminizing estrogen (non-hormonal estrogen), and an activator of sirtuin and has a form of eye drops or eye washes, oral preparation, etc. An agent for treating eye diseases which has excellent treatment effects, reduced in side action can be provided.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, neurodegenerative diseases or disorders, such as Alzheimer's disease, Parkinson's Disease, multiple sclerosis, stroke, ALS Pick's disease, prion disease and Huntington's disease. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of the diseases and disorders.

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

The present invention relates to methods of treating steroid hormone related disorders by modulating steroid hormone activity.

The invention relates to a preparation method of a steroid hormone medicinal intermediate, in particular to a preparation method for a betamethasone intermediate or its analogue. The betamethasone intermediate or its analogue is prepared from a compound I by means of elimination reaction, methylation reaction, cyano-group substitution reaction, siloxy protective reaction, intramolecular nucleophilic substitution reaction and esterification reaction. The method provided by the invention has the characteristics of cheap raw materials, and high and stable yield. The reaction route is as the following, wherein R1 is Cl or Br, and R is H or hydrocarbonyl of C1-C10.

The invention discloses a monolithic column, a preparation method and a application thereof. The preparation method comprises the following steps: 1) polymeric monomer, pore-foaming agent, initiator and cuprous bromide are mixed together and then added with catalyst ligand after being deoxidized; the mixture is put into a chromatographic column tube to react in a sealing way; after the reaction, the chromatographic column tube is connected with a high pressure transfer pump, and the soluble substances such as the pore-foaming agent and the like are rinsed and removed by organic solvent, so that a monolithic column with a three-dimensional continuous skeleton structure is obtained; 2) the mixture of the organic solution, catalyst, catalyst ligand and antioxidant of the functional monomer is injected into the monolithic column, and bromine group remained on the surface of the column body initiates the surface grafting polymerization reaction of vinyl monomer. The method leads polymerization reaction to be carried out at the room temperature, so as to greatly solves the problems of inhomogeneous column body structure, volume contraction and the like caused by high polymerization temperature. Compared with the traditional monolithic column, the obtained monolithic column has obviously different structure, thus being applicable to separating biological macromolecules such as steroid hormone drugs, protein or the like.

The invention discloses a method for producing an important steroid hormone dexamethasone methyl tetraenes (5ST) intermediate, which comprises the following steps of: dissolving a methyl dehydrate into an organic solvent, adding a reducing agent into the solution at the temperature of between 5 DEG C below zero and 20 DEG C, and performing one-step reaction to obtain methyl tetraenes with less than 0.8 percent of single impurity, wherein the reducing agent is a mixed reducing agent of 1 to 15 weight parts of chromium trichloride and 0.2 to 8 weight parts of zinc powder. The method for producing the 5ST shortens the reduction reaction into one-step reaction from three-step reaction so as to save the reaction time and facilitate the operation. The method reduces the consumption of chemical raw materials and dangerous goods, reduces the environmental pollution, and reflects the environment-friendly idea of green chemistry.

Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1, type 2 and/or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The invention relates to a temperature-sensitive in-situ gel preparation composition for intra-articular injection and a preparation method thereof, and belongs to the field of medicine preparations. The preparation method comprises the following steps: preparing diclofenac sodium-carrying sodium alginate microspheres by combining a microsphere technology with a temperature-sensitive gel technology, and then carrying the medicine-carrying microspheres in a chitosan/beta-sodium glycerophosphate temperature-sensitive in-situ gel system to obtain a diclofenac sodium in-situ gel preparation composition. The composition is in a liquid state at a room temperature, capable of being converted to a semi-solid gel at a body temperature and forming a medicine storeroom at a medication part after being partially injected to enter an articular cavity, and beneficial to slowly releasing the medicine, prolonging the time of staying at the injection part, of the medicine, and enhancing the efficacy. The composition disclosed by the invention can be used for treating arthritis diseases of rheumatism, rheumatoid arthritis, osteoarthritis, synovitis and the like, as well as applicable to both diclofenac sodium and other arthritis treatment medicines of non-steroidal anti-inflammatory medicines, steroid hormone medicines, biological preparations and the like.

The invention provides a preparation method for hydroxylation of 11 alpha of an important intermediate of a steroidal hormone substance, and aims to solve the problems that the conversion rate is low and the environment is polluted when a microorganism is used for converting steroidal C11 alpha for hydroxylation in the prior art. The preparation method comprises the following steps: strain breeding, wherein a strain of ochratoxin or rhizopus nigricans is inoculated to a corresponding seed medium for cultivation; substrate emulsification, wherein a substrate selected from one of 17-alpha hydroxyl progesterone, 4-androstenedione or 16,17-alpha epoxy progesterone is subjected to emulsification treatment under the action of a surfactant; fermented cultivation, wherein the ochratoxin or rhizopus nigricans is inoculated to a fermented medium to be cultivated for a period of time, and then one of emulsion liquids of sterilized 17-alpha hydroxyl progesterone, 4-androstenedione or 16,17-alpha epoxy progesterone is added for performing continuous fermented cultivation; extracting a finished product. The method has the advantages of high conversion rate, little pollution, environmental protection, low pressure and the like.

The present disclosure provides for compositions and methods of stimulating reproductive behavior and reproductive success and productivity in a suid, such as pigs. The composition may comprise at least one steroid hormone and a heterocyclic aromatic compound. The method comprises administering the pheromone composition to the suid for a period of time.

The present invention relates to a method for environment-protecting pollutionless production of diosgenin. Before the steps of extraction, concentration and crystallization of conventional method the steps of raw material pretreatment, sieving, membrane filtering and dewatering, fermentation, hydrolysis, filtration, secondary hydrolysis and water-washing are successively implemented or the steps of raw material pretreatment, sieving, membrane filtering and dewatering, adding solvent to make extraction separation to twice, combining extracts, distilling, fermentation and hydrolysis are successively implemented. It has no need of complex special equipment, and can purify and produce diosgenin as basic raw material of steroid hormone medicine by utilizing diascorea plant.

The present invention is directed to methods, pharmaceutical compositions and kits for modulating skeletal muscle precursor cell activation. Modulation is effected through the use of nitric oxide (NO), donors of NO, inhibitors of NO activity (NO inhibitor) or regulators of NO production, either locally or systemically. The invention further teaches the use of NO, an NO donor, an NO inhibitor or a regulator of NO production to modulate the effects of steroid hormone on skeletal muscle. The invention further provides a method for identifying a compound which effects a change in activation state of muscle precursor cells. A number of advantages is evident. By allowing skeletal muscle precursor cells to be manipulated directly, the invention enables specific treatments to regenerate and repair muscle.